Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain "HEROIC"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Patients ≥ 18 years
- Patients with atrial fibrillation
- Patients in treatment with rivaroxaban for stroke prevention in atrial fibrillation at least 3 months previous to inclusion period in study

Exclusion Criteria

- Patients in treatment after start of study
- Patients treated with other anticoagulant treatment